Glycosylated fibronectin stands out as a particularly promising early biomarker, detectable in first-trimester samples from women who subsequently develop PE and strongly associated with adverse outcomes, including hypertension, preterm delivery, and FGR [92]. This evidence concerns the gene FN1 and Hypertension.